The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1029
ISSUE1029
June 19, 1998
Rituximab for Non-Hodgkins Lymphoma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Rituximab for Non-Hodgkins Lymphoma
June 19, 1998 (Issue: 1029)
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.